<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123939</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019B2001X</org_study_id>
    <secondary_id>2016-001991-31</secondary_id>
    <nct_id>NCT03123939</nct_id>
  </id_info>
  <brief_title>Phase III B in Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Phase IIIb Study for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, phase III B study to determine the safety and
      efficacy of CTL019 in pediatric/young adult patients with r/r B-cell ALL.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>patient followed up for one year post infusion</time_frame>
    <description>Safety will be determined by type, frequency and severity of adverse events (AEs) and laboratory abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission (CR)</measure>
    <time_frame>6 months after administration</time_frame>
    <description>CR includes CR + CR with incomplete blood count recovery (CRi).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve CR or CRi at Month 6 without step cell transplantation (SCT)</measure>
    <time_frame>Month 6</time_frame>
    <description>Percentage of patients who achieve CR or CRi at Month 6 without stem cell transplantation (SCT) between CTL019 infusion and Month 6 response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve CR or CRi and then proceed to SCT while in remission prior to month 6</measure>
    <time_frame>prior to month 6</time_frame>
    <description>Percentage of patients who achieve CR or CRi and then proceed to SCT while in remission prior to Month 6 response assessment
In addition, all patients that proceed to SCT after CTL019 infusion will be described</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Month 6, Month 12</time_frame>
    <description>DOR is the time from achievement of CR or CRi, whichever occurs first, to relapse or death due to acute lymphoblastic leukemia (ALL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>RFS is the time from achievement of CR or CRi whichever occurs first to relapse or death due to any cause during CR or CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>EFS is the time from date of CTL019 infusion to the earliest of death, relapse or treatment failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>OS is the time from date of CTL019 infusion to the date of death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and incidence of immunogenicity of antibodies against CTL019</measure>
    <time_frame>Week -16 to Day -1, Month 12</time_frame>
    <description>Describe the prevalence and incidence of immunogenicity of antibodies against CTL019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CTL019 in the blood</measure>
    <time_frame>Day 28, Month 3</time_frame>
    <description>Maximum concentration (Cmax), time to peak concentration (Tmax), area under the curve (AUC) and other relevant kinetic parameters of CTL019 in the blood
Persistence of CTL019 in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Cmax and AUC0-28d of CTL019 in the blood with CRS grade</measure>
    <time_frame>Day 28</time_frame>
    <description>Evaluate the relationship between exposure to CTL019 with Cytokine Release Syndrome (CRS) grades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients attaining CR or CRi at Day 28</measure>
    <time_frame>Day 28 ± 4 days post CTL019 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as a function of baseline tumor burden (tumor load) (minimal residual disease (MRD), extramedullary disease, etc.)</measure>
    <time_frame>Day 28 ± 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) kinetic parameter of CTL019 in the blood</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak concentration (Tmax) kinetic parameter of CTL019 in the blood</measure>
    <time_frame>Day 28, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) kinetic parameter of CTL019 in the blood</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD quantitative result (% leukemic cells) and qualitative result</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CTL019 - traetment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all enrolled subjects will get the study treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTL019</intervention_name>
    <description>0.2 to 5.0 × 10(6) autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10(8) CTL019 transduced viable T cells (for patients &gt; 50 kg).</description>
    <arm_group_label>CTL019 - traetment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Relapsed or refractory B-cell ALL in pediatric or young adult patients:

          1. Second or greater bone marrow relapse.

          2. Any bone marrow relapse after allogeneic SCT and must be ≥ 4 months from SCT at the
             time of CTL019 infusion OR

          3. Primary refractory as defined by not achieving a CR after 2 cycles of a standard
             chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle
             of standard chemotherapy for relapsed leukemia OR

          4. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are
             intolerant to or have failed 2 lines of tyrosine kinase inhibitor (TKI) therapy, or if
             TKI therapy is contraindicated OR

          5. Ineligible for allogeneic SCT

        For relapsed patients, CD19 tumor expression demonstrated in bone marrow or peripheral
        blood by flow cytometry within 3 months of program entry.For relapsed or refractory
        patients previously treated with blinatumomab, CD19 tumor expression must be demonstrated
        (via flow cytometry) at Screening.

        Adequate organ function defined as:

          1. A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL).
             Age Male Female: to &lt; 2 years 0.6 0.6; to &lt; 6 years 0.8 0.8; 6 to &lt; 10 years 1.0 1.0;
             10 to &lt; 13 years 1.2 1.2; 13 to &lt; 16 years 1.5 1.4; ≥ 16 years 1.7 1.4.

          2. ALT ≤ 5 times the upper limit of normal (ULN) for age.

          3. Bilirubin &lt; 2.0 mg/dL.

          4. Minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation
             &gt; 91% on room air.

          5. Left Ventricular Shortening Fraction ≥ 28% by echocardiogram, or Left Ventricular
             Ejection Fraction ≥ 45% by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).

        Life expectancy &gt; 12 weeks.

        Age less than 26 at the time of screening.

        Karnofsky (age ≥16 years) or Lansky (age &lt; 16 years) performance status ≥ 50 at screening.

        Patients previously treated with blinatumomab who have detectable leukemia and documented
        CD19+ expression (via flow cytometry) and confirmed absence of CD19- leukemic blasts at
        Screening may be included. In this case, at least 1 week washout period must be applied
        from last dose of blinatumomab to start of leukapheresis. Patients previously treated with
        blinatumomab with no detectable MRD (i.e. MRD negative demonstrated by leukemic blasts &lt;
        0.01%) will be excluded.

        Must have a leukapheresis product of non-mobilized cells received and accepted by the
        manufacturing site.

        Patients with active CNS leukemia involvement defined as CNS-3 by CSF findings only are
        eligible but will have their CTL019 infusion delayed until CNS disease is reduced to CNS-1
        or CNS-2 by CSF findings. Patients with other forms of active CNS-3 leukemic involvement
        such as CNS parenchymal or ocular disease, cranial nerve involvement or significant
        leptomeningeal disease are not eligible. However, such patients with other forms of CNS-3
        leukemic involvement (non-CSF involvement) are eligible if there is documented evidence of
        disease stabilization for at least 3 months prior to CTL019 infusion. Patients must have no
        acute/ongoing neurologic toxicity &gt; Grade 1 with the exception of a history of controlled
        seizures or fixed neurologic deficits that have been stable/improving over the past 3
        months.

        Exclusion criteria Isolated extra-medullary disease relapse. Concomitant genetic syndromes
        associated with bone marrow failure states: Fanconi anemia, Kostmann syndrome, Shwachman
        syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will
        not be excluded.

        Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia
        with B-cell surface immunoglobulin (sIg) positive and kappa or lambda restricted positivity
        ALL, with FAB L3 morphology and /or a MYC translocation).

        Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative
        intent and with no evidence of active disease.

        Prior treatment with any gene therapy product. Prior treatment with any anti-CD19/anti-CD3
        therapy, or any other anti-CD19 therapy, except for patients pre-treated with blinatumomab
        Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or
        any uncontrolled infection at screening Human immunodeficiency virus (HIV) positive test
        within 8 weeks of screening. Presence of grade 2 to 4 acute or extensive chronic GVHD.
        Uncontrolled acute life threatening bacterial, viral or fungal infection at Screening
        Investigational medicinal product within the last 30 days prior to screening. Pregnant or
        nursing women.Women of child-bearing potential and all male participants, unless they are
        using highly effective methods of contraception for a period of 1 year after the CTL019
        infusion.

        The following medications are excluded:

          1. Steroids: Therapeutic systemic doses of steroids must be stopped &gt; 72 hours prior to
             CTL019 infusion.

          2. Allogeneic cellular therapy: Any donor lymphocyte infusions must be completed &gt; 6
             weeks prior to CTL019 infusion.

          3. GVHD therapies: Any systemic drug used for GVHD must be stopped &gt; 4 weeks prior to
             CTL019 infusion to confirm that GVHD recurrence is not observed.

          4. Chemotherapy:

               -  TKIs and hydroxyurea must be stopped &gt; 72 hours prior to CTL019 infusion.

               -  must be stopped &gt; 1 week prior to CTL019 infusion: vincristine, 6-mercaptopurine,
                  6-thioguanine, methotrexate &lt; 25 mg/m2, cytosine arabinoside &lt; 100 mg/m2/day,
                  asparaginase (non pegylated).

               -  must be stopped &gt; 2 weeks prior to CTL019 infusion: salvage chemotherapy (e.g.
                  clofarabine, cytosine arabinoside &gt; 100 mg/m2, anthracyclines, cyclophosphamide,
                  methotrexate ≥ 25 mg/m2).

               -  Pegylated-asparaginase must be stopped &gt; 4 weeks prior to CTL019 infusion.

          5. CNS disease prophylaxis: CNS prophylaxis treatment must be stopped &gt; 1 week prior to
             CTL019 infusion (e.g. intrathecal methotrexate).

          6. Radiotherapy

               -  Non-CNS site of radiation must be completed &gt; 2 weeks prior to CTL019 infusion.

               -  CNS directed radiation must be completed &gt; 8 weeks prior to CTL019 infusion.

          7. Anti T-cell antibodies: Administration of any T cell lytic or toxic antibody (e.g.
             alemtuzumab) within 8 weeks prior to CTL019 is prohibited Other protocol-defined
             inclusion/exclusion may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakyo Ku</city>
        <state>Kyoto</state>
        <zip>606 8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>CTL019</keyword>
  <keyword>relapsed/refractory pediatric/young adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

